Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study.

The results of the present study suggest that pembrolizumab seems less effective in the real-life population than in the pivotal clinical trials in patients with NSCLC but remains an effective treatment option for patients with NSCLC. Longer follow-up is needed.